King K A, Lim S L, Pang C C
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Eur J Pharmacol. 1995 Aug 4;281(2):187-93. doi: 10.1016/0014-2999(95)00243-e.
The effects of platelet activating factor (PAF) on haemodynamics in the absence and presence of the potent PAF receptor antagonist TCV-309 (3-bromo-5-[N-phenyl-N-[2-[[2-(1,2,3,4-tetrahydro-2- isoquinolyl-carbonyloxy)ethyl]carbamoyl]ethyl]carbamoyl]-1- propylpyridinium nitrate) were studied by the microsphere technique in pentobarbitone-anaesthetized rats. I.v. infusion of the low dose PAF (0.05 microgram kg-1 min-1) did not significantly alter mean arterial pressure, cardiac output or total peripheral resistance but increased arterial conductances in the stomach, intestine, caecum and colon and reduced conductance in the spleen. I.v. infusion of the high dose of PAF (0.3 microgram kg-1 min-1) markedly reduced mean arterial pressure (-53 mm Hg) and cardiac output (-62%) and insignificantly increased total peripheral resistance. Arterial conductances in the lungs, stomach, intestine, caecum and colon, kidneys and spleen were reduced and those in the heart and muscle were increased. TCV-309 (10 micrograms kg-1) abolished all changes in arterial pressure, cardiac output and total peripheral resistance and arterial conductances elicited by either the low or the high dose of PAF. The results show that a non-hypotensive dose of PAF caused vasodilatation of the gastrointestinal organs and vasoconstriction of the spleen. A high dose of PAF which markedly decreased arterial pressure and cardiac output caused vasodilatation of the heart and muscle and vasoconstriction of the lungs (bronchial), gastrointestinal organs, kidneys and spleen. All haemodynamic changes were blocked by TCV-309 indicating the involvement of PAF receptors.
在戊巴比妥麻醉的大鼠中,采用微球技术研究了血小板活化因子(PAF)在不存在和存在强效PAF受体拮抗剂TCV - 309(3 - 溴 - 5 - [N - 苯基 - N - [2 - [[2 - (1,2,3,4 - 四氢 - 2 - 异喹啉基 - 羰氧基)乙基]氨基甲酰基]乙基]氨基甲酰基] - 1 - 丙基吡啶硝酸盐)的情况下对血流动力学的影响。静脉输注低剂量PAF(0.05微克·千克⁻¹·分钟⁻¹)对平均动脉压、心输出量或总外周阻力无显著影响,但增加了胃、肠、盲肠和结肠的动脉传导性,并降低了脾脏的传导性。静脉输注高剂量PAF(0.3微克·千克⁻¹·分钟⁻¹)显著降低了平均动脉压(-53毫米汞柱)和心输出量(-62%),并使总外周阻力略有增加。肺、胃、肠、盲肠、结肠、肾脏和脾脏的动脉传导性降低,而心脏和肌肉的动脉传导性增加。TCV - 309(10微克·千克⁻¹)消除了低剂量或高剂量PAF引起的动脉压、心输出量、总外周阻力和动脉传导性的所有变化。结果表明,非降压剂量的PAF引起胃肠道器官血管舒张和脾脏血管收缩。高剂量的PAF显著降低动脉压和心输出量,导致心脏和肌肉血管舒张以及肺(支气管)、胃肠道器官、肾脏和脾脏血管收缩。所有血流动力学变化均被TCV - 309阻断,表明PAF受体参与其中。